erythromycin has been researched along with paclitaxel in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 9 (30.00) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Arnold, E; Kaul, M; Kerrigan, JE; LaVoie, EJ; Parhi, AK; Pilch, DS; Tuske, S; Zhang, Y | 1 |
| Kaul, M; Kelley, C; LaVoie, EJ; Parhi, A; Pilch, DS; Zhang, Y | 1 |
| Giurleo, D; Kaul, M; LaVoie, EJ; Parhi, A; Pilch, DS; Zhang, Y | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jing, YR; Li, WL; Wang, YF; Zhao, LX; Zhou, W | 1 |
| Alankuş-Çalışkan, Ö; Çapcı-Karagöz, A; Emirdağ-Öztürk, S; Karayıldırım, T; Özmen, A; Poyrazoğlu-Çoban, E | 1 |
| Bachmann, BO; Covington, CL; Derewacz, DK; Marnett, LJ; McNees, CR; Polavarapu, PL; Scalmani, G; Shanmugam, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Alenazy, R; Gu, X; Ma, S; Polyak, SW; Sykes, MJ; Venter, H; Wang, Y; Zhang, N; Zhang, P | 1 |
| Blake, DS; Collins, JM; Jamis-Dow, CA; Klecker, RW; Pearl, ML; Watkins, PB | 1 |
| Dordick, JS; Khmelnitsky, YL; Sergeeva, MV | 1 |
| Collins, JM | 1 |
| Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
| Bauer, CA; Grimme, S | 1 |
| Fushida, S; Hayashi, H; Hirakawa, K; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohbatake, Y; Ohta, T; Oyama, K; Tajima, H; Takamura, H; Tsukada, T; Yashiro, M | 1 |
| O'Connor, SE | 1 |
| Benny, O; Braunstein, R; Fluksman, A; Friedman, N; Hazan, R; Lafuente, A; Nogues, J; Roca, AG; Sepulveda, B; Steinberg, E; Yekhin, Z | 1 |
3 review(s) available for erythromycin and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The evolution of biotransformation technologies.
Topics: Benzopyrans; Biotechnology; Biotransformation; Catalysis; Engineering; Enzymes; Enzymes, Immobilized; Erythromycin; Paclitaxel; Serum Albumin, Bovine | 1998 |
Engineering of Secondary Metabolism.
Topics: Artemisinins; Bacteria; Enzymes; Erythromycin; Escherichia coli; Fungi; Metabolic Engineering; Metabolic Networks and Pathways; Paclitaxel; Plants; Protein Engineering; Secondary Metabolism; Streptomyces | 2015 |
1 trial(s) available for erythromycin and paclitaxel
| Article | Year |
|---|---|
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |
26 other study(ies) available for erythromycin and paclitaxel
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biphenyl Compounds; Cytoskeletal Proteins; Drug Resistance, Multiple; Enterococcus; Guanidines; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Polymerization; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Vancomycin Resistance | 2012 |
3-Phenyl substituted 6,7-dimethoxyisoquinoline derivatives as FtsZ-targeting antibacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cytoskeletal Proteins; Enterococcus faecalis; HEK293 Cells; Humans; Isoquinolines; Molecular Targeted Therapy; Staphylococcus aureus | 2012 |
Substituted 1,6-diphenylnaphthalenes as FtsZ-targeting antibacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cytoskeletal Proteins; Enterococcus faecalis; Microbial Sensitivity Tests; Molecular Structure; Naphthalenes; Polymerization; Staphylococcus aureus | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The synthesis of novel taxoids for oral administration.
Topics: Administration, Oral; Animals; Dogs; Humans; Paclitaxel; Taxoids | 2014 |
Synthesis, antimicrobial and cytotoxic activities, and structure-activity relationships of gypsogenin derivatives against human cancer cells.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Bacillus; Caco-2 Cells; Candida; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HeLa Cells; HL-60 Cells; HT29 Cells; Humans; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Conformation; Saponins; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Structure and Stereochemical Determination of Hypogeamicins from a Cave-Derived Actinomycete.
Topics: Actinobacteria; Caves; Circular Dichroism; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Naphthoquinones; Nuclear Magnetic Resonance, Biomolecular; Optical Rotatory Dispersion; Stereoisomerism | 2014 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Design and structural optimization of novel 2H-benzo[h]chromene derivatives that target AcrB and reverse bacterial multidrug resistance.
Topics: Anti-Bacterial Agents; Benzopyrans; Cell Membrane Permeability; Drug Design; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Hydrogen Bonding; Microbial Sensitivity Tests; Models, Molecular; Multidrug Resistance-Associated Proteins; Protein Binding; Structure-Activity Relationship | 2021 |
Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Female; Humans; Ketoconazole; Ovarian Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel | 1997 |
Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Humans; Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
First principles calculation of electron ionization mass spectra for selected organic drug molecules.
Topics: Chemistry, Pharmaceutical; Erythromycin; Humans; Lovastatin; Paclitaxel; Prescription Drugs; Simvastatin; Spectrometry, Mass, Electrospray Ionization; Tetrazoles; Valine; Valsartan | 2014 |
Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Topics: Animals; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; Erythromycin; Humans; Mice; Orosomucoid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Modular Drug-Loaded Nanocapsules with Metal Dome Layers as a Platform for Obtaining Synergistic Therapeutic Biological Activities.
Topics: Cell Line, Tumor; Erythromycin; Indocyanine Green; Nanocapsules; Paclitaxel; Polymers | 2023 |